GlassScriptPhysician profile
Suzanne M Decker
NPI 1326373457
$1,874.43
in general payments reported to CMS, 2019-2025
18 companies · $704 in 2025
The $704 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $191 · 2023: $427 · 2024: $553 · 2025: $704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,683.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $556.00 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $366.21 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $129.17 | 2024 | Xarelto |
| Glaxosmithkline, LLC. | $126.33 | 2023-2025 | Trelegy Ellipta |
| Pfizer INC. | $90.58 | 2022-2025 | |
| Novo Nordisk INC | $89.53 | 2022-2025 | Ozempic, Rybelsus, Tresiba |
| Amgen INC. | $72.70 | 2022-2025 | Evenity |
| Exact Sciences Corporation | $64.20 | 2023-2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $58.22 | 2023-2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $54.80 | 2024-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $53.09 | 2022-2025 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $51.83 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.36 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $43.99 | 2024-2025 | |
| Dexcom, INC. | $20.65 | 2024 | Dexcom G6 Transmitter |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomerieux INC | $17.00 | 2025 | Biofire Spotfire Control Station |
| Mylan Specialty L.P. | $16.58 | 2022 | |
| Phathom Pharmaceuticals, INC. | $13.19 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Decker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.